失败血管腔内主动脉瘤修复的外科移植或开窗分支血管腔内修复管理
本回顾性分析纳入1999-2016年247例失败EVAR患者,其中162例接受外科移植(explantation),85例接受开窗分支EVAR(F/B-EVAR)。F/B-EVAR组30天死亡率(5% vs 10%,P=0.0192)和动脉瘤相关死亡率(HR 0.0683,95%CI 0.01-0.44,P=0.0048)更低,但再干预率无差异。
要点
- 失败EVAR后F/B-EVAR组30天死亡率5%,低于移植组10%(P=0.0192)。
- F/B-EVAR组动脉瘤相关死亡率更低(HR 0.0683,95%CI 0.01-0.44,P=0.0048)。
- 所有急诊(n=24,10%)和感染(n=28,11%)病例均采用开放转换治疗。
核心结论
- 外科移植和F/B-EVAR是治疗失败EVAR的必要选择,两种技术结果具有竞争力。
- 不同失败模式可能指向优先的治疗方法;失败EVAR的挽救应根据每位患者的表现和可用资源个体化。
研究设计与样本
- 回顾性分析1999-2016年247例失败EVAR患者,其中162例接受外科移植,85例接受F/B-EVAR。
- F/B-EVAR在医师赞助的研究性器械豁免下进行。
- 统计分析包括多因素logistic回归、Fisher精确检验和χ2检验。
主要发现
- 患者多数为男性(n=216,87%),平均年龄75岁(范围50-93岁)。
- F/B-EVAR组距初次EVAR的平均时间更高(46±7个月 vs 69±41个月;P<.001)。
- 移植组和F/B-EVAR组内漏均为最常见失败原因(75% vs 64%;P=.052)。
- I型内漏在F/B-EVAR组更常见(64% vs 40%;P<.001),II型内漏在开放修复组更常见(28% vs 2%;P<.001)。
- 移植物移位(12% vs 26%;P=.005)和瘤颈退变/疾病进展(14% vs 59%;P<.001)在F/B-EVAR组更常见,而动脉瘤增大在移植组更常见(68% vs 33%;P<.001)。
关键数值与推荐
- 30天再干预率在F/B-EVAR组与移植组间无差异(OR 0.6258;95%CI 0.2-1.86;P=.4115)。
- 30天死亡率在F/B-EVAR组更低(5% vs 10%;P=.0192)。
- 动脉瘤相关死亡率在F/B-EVAR组更低(HR 0.0683;95%CI 0.01-0.44;P=.0048)。
- 排除急诊和感染的亚组分析未改变再干预无差异(P=.1175)、30天死亡率(P=.6329)或动脉瘤相关死亡率(P=.7849)的结果。
临床怎么用
- 外科移植和F/B-EVAR是失败EVAR的必要治疗选择,两种技术结果具有竞争力。
- 不同失败模式可能指向优先的治疗方法;失败EVAR的挽救应根据每位患者的表现和可用资源个体化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The incidence of failed endovascular aneurysm repair (EVAR) is increasing, and understanding the different methods of management and repair is paramount. The objective of this study was to evaluate the clinical management and rescue of failed EVAR by either explantation or fenestrated-branched EVAR (F/B-EVAR). METHODS: A retrospective analysis (1999-2016) of 247 patients who underwent either explantation (n = 162) or F/B-EVAR (n = 85) for failed EVAR was performed. F/B-EVAR was performed under a physician-sponsored investigational device exemption. Demographics of the patients, clinical presentation and failure etiology, perioperative management, rate of reinterventions, morbidity, and mortality were analyzed. Those undergoing surgical explantation were compared with those undergoing F/B-EVAR conversion. Statistical analysis included multivariable logistic regressions, Fisher exact test, and χ2 test. RESULTS: The majority of patients were male (n = 216 [87%]), with a mean age of 75 years (range, 50-93 years). The mean time from primary EVAR was higher in F/B-EVAR (46 ± 7 months vs 69 ± 41 months; P < .001). Graft manufacturer did not differ between those requiring explantation and those having endovascular rescue (P = .170). All emergencies (n = 24 [10%]) and infections (n = 28 [11%]) were treated with open conversion. Endoleak was the most common reason for failure in both explantation and F/B-EVAR groups (75% vs 64%, respectively; P = .052). Type I endoleak was the most common endoleak reported in both groups, occurring more frequently in F/B-EVAR (64% vs 40%; P < .001); type II endoleak was more common in those undergoing open repair (28% vs 2%; P < .001). Graft migration (12% vs 26%; P = .005) and neck degeneration/disease progression (14% vs 59%; P < .001) were more prevalent in F/B-EVAR, but aneurysm enlargement was more common in explantation (68% vs 33%; P < .001). Thirty-day reintervention rates did not differ between F/B-EVAR and explantation (odds ratio, 0.6258; 95% confidence interval, 0.2-1.86; P = .4115); however, 30-day mortality was lower in the F/B-EVAR group (5% vs 10%; P = .0192). Similarly, aneurysm-related mortality was also lower in the F/B-EVAR group (hazard ratio, 0.0683; 95% confidence interval, 0.01-0.44; P = .0048). A subset analysis excluding emergencies and infections did not alter the lack of difference in terms of freedom from reinterventions (P = .1175), 30-day mortality (P = .6329), or aneurysm-related mortality (P = .7849). CONCLUSIONS: Explantation and F/B-EVAR are necessary options in treating patients with failed EVAR, and both techniques have competitive results. Different modes of failure may point to a preferred method of treatment; consequently, rescue of failed EVAR should be individualized according to each patient's presentation and resources available.
引用
- Dias AP, Farivar BS, Steenberge SP, et al. Management of failed endovascular aortic aneurysm repair with explantation or fenestrated-branched endovascular aortic aneurysm repair. J Vasc Surg. 2018. PMID: 29937284. doi:10.1016/j.jvs.2018.03.418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。